Publications by authors named "M Debiossat"

Background: Soluble oligomeric forms of Tau protein have emerged as crucial players in the propagation of Tau pathology in Alzheimer's disease (AD). Our objective is to introduce a single-domain antibody (sdAb) named 2C5 as a novel radiotracer for the efficient detection and longitudinal monitoring of oligomeric Tau species in the human brain.

Methods: The development and production of 2C5 involved llama immunization with the largest human Tau isoform oligomers of different maturation states.

View Article and Find Full Text PDF

Background: Despite the development of positron emission tomography (PET), single photon emission computed tomography (SPECT) still accounts for around 80% of all examinations performed in nuclear medicine departments. The search for new radiotracers or chelating agents for Technetium-99m is therefore still ongoing. O-TRENSOX and O-TRENOX two synthetic siderophores would be good candidates for this purpose as they are hexadentate ligands based on the very versatile and efficient 8-hydroxyquinoline chelating subunit.

View Article and Find Full Text PDF

In this study, six vacuum liquid chromatography (VLC) fractions (F1-F6) of the -BuOH extract of Murb. (BELN) were examined for their anticancer capacity. The composition of secondary metabolites was analyzed by LC-HRMS/MS.

View Article and Find Full Text PDF

Context: is the largest genus of the Linaceae family; the species of this genus are known to have anticancer activity.

Objective: In this study, ethyl acetate extracts of Murb. (EAELN) and L.

View Article and Find Full Text PDF

Purpose: Coronary microvascular dysfunction (CMVD) plays a major role in the occurrence of cardiovascular events (CVE). We recently suggested the clinical potential of myocardial perfusion entropy (MPE) quantification from SPECT myocardial perfusion images (MPI) for the prognosis of CVE occurrence. We hypothesized that the quantification of MPE from SPECT MPI would allow the assessment of CMVD-related MPE variations in a preclinical model of type 2 diabetes (T2D) including treatment with the anti-diabetic incretin liraglutide (LIR).

View Article and Find Full Text PDF